Calendario›REGN›REGN1908

REGN1908

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

Ensayo de REGENERON PHARMACEUTICALS, INC. en Conjuntivitis alergica.

Más ensayos de: Conjuntivitis alérgica.

Fase

Fase 3

Estado

Completado

Participantes

64

previstos

Centros

4

Fin del objetivo primario

may 2025

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en nov 2024.

Qué mide

Ocular itch score (At day 8 post-Conjunctival Allergen Challenge (CAC)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06602726), actualizada en may 2026.